Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises the Private Equity-fund SSVP on acquisition of EuroMaint
Mandate

Vinge advises the Private Equity-fund SSVP on acquisition of EuroMaint

October 26, 2016

Vinge is advising SSVP, a fund advised by Private Equity advisor Orlando Nordics, in connection with the acquisition of all the shares in EuroMaint Gruppen AB (“EuroMaint”) from Ratos AB (publ.).

EuroMaint is a leading independent maintenance provider for the Swedish rail transport industry, and has a network of workshops from Luleå in the north to Malmö in the south of Sweden. EuroMaint head office is located in Solna, Sweden and the company has approximately 1050 employees. The transaction is conditional upon approval from competition authorities.

Vinge’s team includes, inter alia, Magnus Hedsund, Anna Edström, Kristoffer Franzkeit, Jessica Salomonsson (M&A), Mathias Lindquist (environmental law), Maria Schultzberg (tax) and Fabian Ekeblad, Adam Sandberg and Josefine Lanker (financing).

Related

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of MedMera Bank AB

 Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of all shares in MedMera Bank AB from Kooperativa Förbundet for a total consideration of SEK 1,960 million. The transaction positions Morrow Bank as a leading Nordic platform in consumer finance with combined gross loans of SEK 28.2 billion.
March 24, 2026

Vinge advises NEWS, a portfolio company of Litorina, in connection with the sale of Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG

 Vinge advises Northern Environmental and Water Solutions AB (“NEWS”), a portfolio company of Litorina, in connection with the sale of the operating subsidiaries Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG (Vienna Stock Exchange: WIE). The transaction is expected to be completed in Q2 2026.
March 24, 2026

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026